CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 207 enrolled / 207 target
Drug / intervention
XPro1595 +1 moredrug
Likely dose
1.0 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05318976
NCT05318976Phase 2CompletedMonitor (4.0/mo)Completion was 13mo ago
CompareCT.gov

A Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation

Inmune Bio, Inc.·interventional·Posted Apr 8, 2022·Updated Jun 29, 2026

In Brief

A Phase 2 clinical trial evaluating XPro1595 and Placebo for Alzheimer Disease and 9 related conditions. Completed, enrolled 207 participants across 41 sites in 8 countries.

Signals

Enrolling slower than its timeline implies

Detailed Summary

The goal of this Phase 2 Alzheimer's study is to determine whether 1.0 mg/kg XPro1595 confers a benefit on cognition, function, and biomarkers of white matter and to further evaluate safety and tolerability. The objectives of this study are to determine the safety, tolerability, and efficacy of XPro1595 in patients with early ADi.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders, Mild Cognitive Impairment
CountriesAustralia, Canada, Czechia, France, Germany, Poland, Spain, United Kingdom
Collaborators--

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedApr 8, 2022
Enrollment StartFeb 28, 2022
Primary CompletionMay 12, 2025
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 4.2 years ago

Arms & Interventions

1.0 mg/kg XPro1595experimental

1.0 mg/kg of XPro1595 will be administered via subcutaneous injection once a week for 23 weeks.

Drug: XPro1595
1.0 mg/kg Placeboplacebo_comparator

1.0 mg/kg of Placebo will be administered via subcutaneous injection once a week for 23 weeks.

Drug: Placebo

Interventions

XPro1595drug

XPro1595 will be delivered by subcutaneous injection once a week

Placebodrug

Placebo will be delivered by subcutaneous injection once a week